CLBFX
Price
$33.35
Change
+$1.62 (+5.11%)
Updated
Apr 9 closing price
Net Assets
217.49B
JBATX
Price
$27.32
Change
+$1.30 (+5.00%)
Updated
Apr 9 closing price
Net Assets
5.12B
Ad is loading...

CLBFX vs JBATX

Header iconCLBFX vs JBATX Comparison
Open Charts CLBFX vs JBATXBanner chart's image
American Funds American Balanced 529F
Price$33.35
Change+$1.62 (+5.11%)
VolumeN/A
Net Assets217.49B
JHancock Balanced R2
Price$27.32
Change+$1.30 (+5.00%)
VolumeN/A
Net Assets5.12B
CLBFX vs JBATX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CLBFX vs. JBATX commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLBFX is a Buy and JBATX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
CLBFX has more cash in the bank: 217B vs. JBATX (5.12B). CLBFX pays higher dividends than JBATX: CLBFX (2.14) vs JBATX (1.53). CLBFX was incepted earlier than JBATX: CLBFX (23 years) vs JBATX (13 years). JBATX (1.13) is less costly to investors than CLBFX (0.68). CLBFX is a more actively managed with annual turnover of: 171.00 vs. JBATX (67.00). JBATX has a lower initial minimum investment than CLBFX: JBATX (0) vs CLBFX (250). CLBFX annual gain was more profitable for investors over the last year : -3.46 vs. JBATX (-5.45). JBATX return over 5 years is better than : 38.04 vs. CLBFX (32.93).
CLBFXJBATXCLBFX / JBATX
Total Expense Ratio0.681.1261%
Annual Report Gross Expense Ratio0.681.1360%
Fund Existence23 years13 years-
Gain YTD-6.926-8.61080%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets217B5.12B4,238%
Annual Yield % from dividends2.141.53140%
Returns for 1 year-3.46-5.4564%
Returns for 3 years6.596.6499%
Returns for 5 years32.9338.0487%
Returns for 10 years54.0450.22108%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VHIAX30.18N/A
N/A
JPMorgan Growth Advantage A
ETCGX34.85N/A
N/A
Eventide Gilead C
SMFYX31.62N/A
N/A
American Beacon Stephens Mid-Cap Gr Y
IGFSX14.43N/A
N/A
VY® Morgan Stanley Global Franchise S2
RECRX10.62N/A
N/A
RBC Emerging Markets Ex-China Equity R6